ScienHub Research Support Develops the Thalassa 2.0 Trial for Long COVID
The Fights Infections Foundation and PharmaMar have launched the Thalassa 2.0 trial to evaluate the efficacy of plitidepsin in patients with long COVID. ScienHub Research Support will oversee the study’s execution with patients from the Hospital Universitari Germans Trias i Pujol, in collaboration with IrsiCaixa.
The phase II study will include 90 patients divided into three groups: one will receive plitidepsin in four cycles, another will receive two cycles of placebo followed by two of plitidepsin, and the third will receive only a placebo.
Primary objective: Assess health changes using the PROMIS-29® system.
Secondary objective: Analyze the safety and tolerability of plitidepsin.
This project strengthens ScienHub’s commitment to researching innovative treatments.